User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The economics of temozolomide in brain cancer.

Primary tabs

Crott, Ralph

For 30 years, nitrosourea was the only adjuvant treatment available for aggressive glioma patients, despite its severe side effects; and, therefore, radiotherapy was often the therapy of choice. Survival prospect in these patients was, however, low with generally few patients surviving beyond 2 years. Recently, temozolomide was successfully tested in a number of randomised clinical trials and showed an increased survival. As many countries are considering reimbursement or have granted a market authorisation for temozolomide, a number of studies have been published in various countries in order to assess the cost-effectiveness of temozolomide for glioma patients in first- or second-line treatment. These studies show that in general, the incremental cost-effectiveness of temozolomide as adjuvant treatment, albeit at the higher end of commonly accepted thresholds, falls in line with other accepted cancer treatments.

Document type Article de périodique (Journal article) – Journal Article, Review
Publication date 2007
Journal information "Expert opinion on pharmacotherapy" - Vol. 8, no. 12, p. 1923-9 (2007)
Peer reviewed yes
issn 1465-6566
e-issn 1744-7666
Publication status Publié
Affiliation UCL
MESH Subject Antineoplastic Agents, Alkylating - economics - therapeutic use ; Brain Neoplasms - drug therapy - economics - radiotherapy ; Combined Modality Therapy ; Cost-Benefit Analysis ; Dacarbazine - analogs & derivatives - economics - therapeutic use ; Glioma - drug therapy - economics - radiotherapy ; Humans ; Quality of Life ; Randomized Controlled Trials as Topic ; Survival Rate
Links
  1. Bleehen NM, Stenning SP, A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, 10.1038/bjc.1991.396
  2. Brada M., Hoang-Xuan K., Rampling R., Dietrich P-Y., Dirix L. Y., Macdonald D., Heimans J. J., Zonnenberg B. A., Bravo-Marques J. M., Henriksson R., Stupp R., Yue N., Bruner J., Dugan M., Rao S., Zaknoen S., Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, 10.1023/a:1008382516636
  3. van den Bent M.J., Taphoorn M.J.B., Brandes A.A., Menten J., Stupp R., Frenay M., Chinot O., Kros J.M., van der Rijt C.C.D., Vecht Ch.J., Allgeier A., Gorlia T., Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971, 10.1200/jco.2003.12.015
  4. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, 10.1016/s0140-6736(02)08091-1
  5. Stupp Roger, Mason Warren P., van den Bent Martin J., Weller Michael, Fisher Barbara, Taphoorn Martin J.B., Belanger Karl, Brandes Alba A., Marosi Christine, Bogdahn Ulrich, Curschmann Jürgen, Janzer Robert C., Ludwin Samuel K., Gorlia Thierry, Allgeier Anouk, Lacombe Denis, Cairncross J. Gregory, Eisenhauer Elizabeth, Mirimanoff René O., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, 10.1056/nejmoa043330
  6. Taphoorn Martin JB, Stupp Roger, Coens Corneel, Osoba David, Kortmann Rolf, van den Bent Martin J, Mason Warren, Mirimanoff René O, Baumert Brigitta G, Eisenhauer Elizabeth, Forsyth Peter, Bottomley Andrew, Health-related quality of life in patients with glioblastoma: a randomised controlled trial, 10.1016/s1470-2045(05)70432-0
  7. OSOBA, J. Clin. Oncol., 18, 1481 (2000)
  8. Osoba D, Brada M, Yung W.K.A, Prados M.D, Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide, 10.1016/s0959-8049(00)00165-9
  9. Wasserfallen Jean-Blaise, Ostermann Sandrine, Pica Alessia, Mirimanoff Ren�-Olivier, Leyvraz Serge, Villemure Jean-Guy, Stupp Roger, Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death, 10.1002/cncr.20619
  10. Wasserfallen J.-B., Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death, 10.1215/s1152851704000687
  11. Stupp R., Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide, 10.1200/jco.20.5.1375
  12. Greanya ED, Taylor SCM, BscPharm F Hu, Barnett J, Thiessen B, Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis, 10.1191/1078155204jp138oa
  13. Martikainen Janne A, Kivioja Akseli, Hallinen Taru, Vihinen Pia, Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme : , 10.2165/00019053-200523080-00006
  14. DINNES, Health Technol. Assess., 5, 1 (2001)
  15. Dinnes J, Cave C, Huang S, Milne R, A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma, 10.1038/sj.bjc.6600135
  16. UYL-DE GROOT CA, LEIDA ML, MAIWENN Jet al.: Cost-effectiveness of temozolomide for the treatment of newly diagnosed gliobastoma multiforme in the UK.ISPOR 8th European Congress, Florence (6 – 8 November 2005) (Abstract).
  17. FRIEDMAN, Clin. Cancer. Res., 6, 2585 (2000)
  18. Hegi Monika E., Diserens Annie-Claire, Gorlia Thierry, Hamou Marie-France, de Tribolet Nicolas, Weller Michael, Kros Johan M., Hainfellner Johannes A., Mason Warren, Mariani Luigi, Bromberg Jacoline E.C., Hau Peter, Mirimanoff René O., Cairncross J. Gregory, Janzer Robert C., Stupp Roger, MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma, 10.1056/nejmoa043331
  19. Stupp Roger, van den Bent Martin J., Hegi Monika E., Optimal role of temozolomide in the treatment of malignant gliomas, 10.1007/s11910-005-0047-7
  20. Stupp R., Changing Paradigms--An Update on the Multidisciplinary Management of Malignant Glioma, 10.1634/theoncologist.11-2-165
  21. Mirimanoff René-Olivier, Gorlia Thierry, Mason Warren, Van den Bent Martin J., Kortmann Rolf-Dieter, Fisher Barbara, Reni Michele, Brandes Alba A., Curschmann Jüergen, Villa Salvador, Cairncross Gregory, Allgeier Anouk, Lacombe Denis, Stupp Roger, Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial, 10.1200/jco.2005.04.5963
  22. Reardon David A., Rich Jeremy N., Friedman Henry S., Bigner Darell D., Recent Advances in the Treatment of Malignant Astrocytoma, 10.1200/jco.2005.04.5302
  23. DiMasi Joseph A., Paquette Cherie, The Economics of Follow-on Drug Research and Development : Trends in Entry Rates and the Timing of Development, 10.2165/00019053-200422002-00002
  24. DiMasi Joseph A., Grabowski Henry G., Economics of New Oncology Drug Development, 10.1200/jco.2006.09.0803
Bibliographic reference Crott, Ralph. The economics of temozolomide in brain cancer.. In: Expert opinion on pharmacotherapy, Vol. 8, no. 12, p. 1923-9 (2007)
Permanent URL http://hdl.handle.net/2078.1/26659